Date: 2016-10-25
Type of information: Development agreement
Compound: atexakin alfa
Company: Relief Therapeutics (Switzerland) FirstString Research (USA - CA)
Therapeutic area: Mental diseases - CNS diseases
Type agreement: development
Action mechanism: protein. Atexakin alfa is a low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with a Merck Serono, and has been the subject of multiple clinical trials and representing a major capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy.
Disease: diabetic neuropathy
Details: * On October 25, 2016, Relief Therapeutics announced a strategic collaboration agreement between its subsidiary Relief Therapeutics SA and FirstString Research for the support of the clinical development in the United States of atexakin alfa, a low-dose formulation of recombinant human interleukin 6 (rhIL-6). Under the terms of this collaboration agreement, FirstString will seek US government financial support, develop relevant collaborations, and provide resources towards the FDA requirements on the constitution of an Investigational New Drug (IND) application dossier for atexakin alfa in diabetic neuropathy. This collaboration is in line with the intention of both companies, operating in the area of diabetic complications, to develop a stronger research and commercial relationship.
Financial terms:
Latest news:
